parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.00 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including oligodendrocyte progenitor cells; strongest in fibro-adipogenic progenitors	0.75
chemistry Open Targets	hard to drug	0.00
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	1 Parkinson's papers of 97	0.91
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 14777

receipt 14783: PID1 in dopamine neurons, braak

power: full sample +0.48 (p 0.042, n 18), 95% CI +0.02 to +0.78. the interval excludes zero: something may be there, smaller than a half can see.
confounder: adjusted for sex: +0.48 (p 0.042, n 18). holds up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.37 (p 0.135, n 18). could be the mix.
skeptic: leave-one-out range +0.41 to +0.56, sign flips 0; without severely affected donors +0.48 (p 0.042, n 18). robust.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for PID1 in dopamine neurons.

case closed: nothing better to follow up.

receipt 14782: PID1 in oligodendrocytes, braak

power: full sample -0.06 (p 0.820, n 18), 95% CI -0.51 to +0.42. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.09 (p 0.728, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.01 (p 0.956, n 18). could be the mix.
skeptic: leave-one-out range -0.18 to +0.08, sign flips 4; without severely affected donors -0.06 (p 0.820, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for PID1 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts